Chimeric polynucleotides and polypeptides enabling the secretion of a polypeptide of interest in combination with exosomes and uses thereof
The present invention provides a chimeric polypeptide comprising a plurality of polypeptide domains that are capable of being secreted in combination with membrane vesicles and in particular exosomes. The invention also concerns the use of polypeptides of the invention and polynucleotides coding for these polypeptides, for the production of immunogenic compositions based on exosomes or DNA, to screen protein interactions. The present invention also concerns exploiting the properties of exosomes comprising a polypeptide of the invention and immunogenic compositions of the invention in immunology. The present invention concerns the use of exosomes comprising a polypeptide of the invention as a diagnostic tool. The present invention also concerns exploiting the properties of membrane vesicles and protein compositions of the invention for the prophylaxis and/or treatment of a disease due to a functional deficit, in particular to transport a protein or a nucleic acid, in particular to compensate for or make up for an enzymatic deficit, or in particular to induce a transcriptional or translational modification in the target cells or organs.
1. An exosome comprising a first chimeric polypeptide, wherein said first chimeric polypeptide is bound to the inner surface of the membrane of said exosome, without passing through said membrane, wherein said first chimeric polypeptide comprises
(i) a peptide or polypeptide of interest,
(ii) a membrane-anchoring domain, which binds the peptide or polypeptide of (i) to the inner surface of the membrane of said exosome, without being inserted into the lipid bilayer, wherein the amino acid sequence of said membrane-anchoring domain is
a) the sequence of a fragment of a protein of the Src family, wherein said fragment comprises the amino acid sequence M-G-X1-X2-X3-S(SEQ ID NO: 125) or M-G-X1-X2-X3-C(SEQ ID NO: 126), in which X1, X2, and X3 independently designate any amino acid residue, or
b) a sequence, which is at least 90% identical to said sequence of a), and which still comprises the amino acid sequence M-G-X1-X2-X3-S(SEQ ID NO: 125) or M-G-X1-X2-X3-C(SEQ ID NO: 126), in which X1, X2, and X3 independently designate any amino acid residue,
and
(iii) an exosome-addressing domain, the amino acid sequence of which is at least 60% identical to the sequence of SEQ ID NO: 8 and with the C-terminal amino acids being PXP wherein X is an amino acid other than C and is a non-palmytilable amino acid,
wherein said exosome-addressing domain comprises at least one PSAP (SEQ ID NO: 88) motif and at least one YxxL (SEQ ID NO: 127) or DYxxL (SEQ ID NO: 128) motif, wherein x independently represents any amino acid residue, and
wherein said first chimeric polypeptide does not comprise any transmembrane domain and does not comprise any signal peptide for importation into the endoplasmic reticulum.
2. A therapeutic composition, the active principle of which comprises one or more exosome(s) of claim 1 .
3. A method for producing antibodies directed against one or more antigenic peptide(s) or polypeptide(s), wherein said method comprises:
a) administering exosomes of claim 1 to a non-human animal to induce the production of antibodies in said non-human animal, wherein the peptide or polypeptide of interest of the first chimeric polypeptide of said exosomes of claim 1 comprises said antigenic peptide(s) or polypeptide(s); and
b) recovering from said non-human animal antibodies, which specifically bind to said antigenic peptide(s) or polypeptide(s).
4. A method for producing monoclonal antibody(ies) directed against one or more antigenic peptide(s) or polypeptide(s), wherein said method comprises
a) fusing spleen cells with myeloma cells to produce hybridomas, wherein said spleen cells have been collected from an animal, to which exosomes of claim 1 have been administered, wherein the peptide or polypeptide of interest of the first chimeric polypeptide of said exosomes of claim 1 comprises said antigenic peptide(s) or polypeptide(s);
b) culturing the hybridomas produced at step a) to produce monoclonal antibodies; and
c) recovering monoclonal antibody(ies), which is(are) directed against said antigenic peptide(s) or polypeptide(s), among the monoclonal antibodies produced at step b).
5. The exosome of claim 1 , which, in addition to said first chimeric polypeptide, further comprises a second chimeric polypeptide, wherein said second chimeric polypeptide passes through the membrane of said exosome, and wherein said second chimeric polypeptide comprises
(i) a peptide or polypeptide of interest, wherein said peptide or polypeptide of interest is identical to, or different from, the peptide or polypeptide of interest of said first chimeric polypeptide;
(ii) a transmembrane domain; and
(iii) an exosome-addressing domain, the amino acid sequence of which is at least 60% identical to the sequence of SEQ ID NO: 8 and with the C-terminal amino acids being PXP wherein X is an amino acid other than C and is a non-palmytilable amino acid,
wherein said exosome-addressing domain comprises at least one PSAP (SEQ ID NO: 88) motif and at least one YxxL (SEQ ID NO: 127) or DYxxL (SEQ ID NO: 128) motif, wherein x independently represents any amino acid residue.
6. A method for in vitro screening molecules for their capacity to interact with a peptide or a polypeptide of interest, wherein said method comprises
a) bringing exosomes of claim 5 into contact with said molecules, wherein said peptide or polypeptide of interest is comprised in the second chimeric polypeptide of said exosomes of claim 5 and is exposed on the outside of said membrane vesicle; and
b) detecting molecules, which interact with said peptide or polypeptide of interest exposed on the outside of said membrane exosome, among the molecules contacted at step a).
7. The exosome of claim 1 , which, in addition to said first chimeric polypeptide, further comprises at least one second chimeric polypeptide, wherein said second chimeric polypeptide passes through the membrane of said exosome, and wherein said at least one second chimeric polypeptide comprises
(i) a peptide or polypeptide of interest, wherein said peptide or polypeptide of interest is identical to, or different from, the peptide or polypeptide of interest of said first chimeric polypeptide;
(ii) a transmembrane domain; and
(iii) an exosome-addressing domain, the amino acid sequence of which is at least 60% identical to the sequence of SEQ ID NO: 8 and with the C-terminal amino acids being PXP wherein X is an amino acid other than C and is a non-palmytilable amino acid,
wherein said exosome-addressing domain comprises at least one PSAP (SEQ ID NO: 88) motif and at least one YxxL (SEQ ID NO: 127) or DYxxL (SEQ ID NO: 128) motif, wherein x independently represents any amino acid residue; and
wherein said peptide or polypeptide of interest of said second chimeric polypeptide is exposed, in part or in its entirety, to the outside of said membrane exosome.
8. The exosome claim 1 , wherein said domains (i) to (iii) are in the following N-term to C-term order: (ii)-(i)-(iii) or (ii)-(iii)-(i); or
wherein said domain (i) consists of two non-contiguous portions, wherein a first of said two non-contiguous portions is in N-term of said domains (ii) and (iii), and wherein the second of said two non-contiguous portions is in C-term of said domains (ii) and (iii).
9. The exosome of claim 1 , wherein said exosome-addressing domain of (iii) comprises two or three YxxL (SEQ ID NO: 127) motifs, wherein x represents any residue.
10. The exosome of claim 1 , wherein said exosome-addressing domain of (iii) comprises at least one YxxL or DYxxL motif selected from YINL, YSHL and DYINL.
11. The exosome of claim 1 , wherein said membrane-anchoring domain of (ii) binds said peptide or polypeptide of (i) to the inner surface of the membrane of said exosome, via a lipid, a fatty acid, a myristic acid, a palmitic acid, a geranyl-geranyl, a farnesyl or a FYVE domain.
12. The exosome of claim 1 , wherein, in said M-G-X1-X2-X3-S(SEQ ID NO: 125) or M-G-X1-X2-X3-C(SEQ ID NO: 126) sequence,
X1 is C, S or L; and/or
X2 is S, I, V, M or L; and/or
X3 is K, Q, H, F, C or S.
13. The exosome of claim 1 , wherein said membrane-anchoring domain of (ii) comprises a plurality of basic amino acid residues.
14. The exosome of claim 1 , wherein said protein of the Src family of claim 1 (ii) a) is the Src, Yes, Lyn, Fyn, Lck, Blk, Fgr, Hck or Yrk protein.
15. The exosome of claim 1 , wherein said fragment of claim 1 (ii) a), which comprises the amino acid sequence M-G-X1-X2-X3-S(SEQ ID NO: 125) or M-G-X1-X2-X3-C(SEQ ID NO: 126), comprises or consists of the amino acid sequence M-G-S-S-K-S-K-P-K-D-P-S-Q-R-R-R (SEQ ID NO: 104) or the amino acid sequence G-S-S-K-S-K-P-K-D-P-S-Q-R-R-R-K-S-R-G-P-G-G (SEQ ID NO: 105).
16. The exosome of claim 1 , wherein said first chimeric polypeptide further comprises at least one linker linking two of said (i)-(iii) domains together and wherein said linker is a peptide or a polypeptide.
17. The exosome of claim 1 , wherein said exosome-addressing domain of (iii) comprises the sequence PxxPxxxxPxxPxxxYxxLxPxxPExYxxLxPxxPDYxxL (SEQ ID NO: 130).
18. The exosome of claim 1 , wherein the sequence of said exosome-addressing domain of (iii) consists of the sequence of SEQ ID NO: 12.
19. The exosome of claim 1 , wherein said exosome-addressing domain of (iii) does not comprise the sequence KCLTSRLLKLLRQ (SEQ ID NO: 129).
20. The exosome of claim 1 , wherein the peptide or polypeptide of interest of said first chimeric polypeptide comprises one or more domain(s) of a cytosolic protein, or one or more fragment(s) of said cytosolic protein domain(s).
21. The exosome of claim 1 , wherein the peptide or the polypeptide of interest of said first chimeric polypeptide comprises or consists of a fragment from a protein of a pathogenic organism, a pathogenic agent, a tumoral antigen, a cytoplasmic antigen, or a ligand receptor.
22. A therapeutic composition, the active principle of which comprises one or more exosome(s) of claim 1 .
23. A therapeutic composition, the active principle of which comprises one or more exosome(s) of claim 7 .
24. The exosome of claim 1 , wherein said fragment of (ii) a) comprises the amino acid sequence M-G-X1-X2-X3-C(SEQ ID NO: 126), in which X1, X2, and X3 independently designate any amino acid residue, and wherein said sequence of (ii) b) is at least 60% identical to said sequence of (ii) a) and still comprises the amino acid sequence M-G-X1-X2-X3-C(SEQ ID NO: 126), in which X1, X2, and X3 independently designate any amino acid residue.
25. The exosome of claim 1 , wherein the peptide or polypeptide of interest of said first chimeric polypeptide comprises one or more domain(s) of a nuclear protein, or one or more fragment(s) of said nuclear protein domain(s).
26. The exosome of claim 1 , wherein said non-palmytilable amino acid is the amino acid A.
27. The exosome of claim 5 , wherein said non-palmytilable amino acid is the amino acid A.
28. The exosome of claim 7 , wherein said non-palmytilable amino acid is the amino acid A.
29. The exosome of claim 1 , wherein the amino acid sequence of said exosome-addressing domain is at least 70% or 80% identical to SEQ ID NO: 8 and with the C-terminal amino acids being PXP wherein X is an amino acid other than C and is a non-palmytilable amino acid.
30. The exosome of claim 1 , wherein the amino acid sequence of said exosome-addressing domain is at least 90% or 95% identical to SEQ ID NO: 8 and with the C-terminal amino acids being PXP wherein X is an amino acid other than C and is a non-palmytilable amino acid.
31. The exosome of claim 1 , which, in addition to said first chimeric polypeptide, further comprises at least one second chimeric polypeptide, wherein said second chimeric polypeptide passes through the membrane of said exosome.